Podcasts about pulmonary arterial hypertension pah

In this episode of the podcast we speak to Steve Smith, a patient advocate who is living with Pulmonary Arterial Hypertension (PAH), a rare and progressive condition characterized by narrowing of the blood vessels in the heart and lungs. Steve is a college administrator and avid theater participant who uses his PAH story to connect with others, believing that open communication is key to the patient experience.   Hear More About Steve and Other PAH patients: OutnumberPAH.com   Editor's Note: Chronic conditions and rare diseases don't discriminate. Patient Worthy and our partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a story to share, learn more about how your voice can help spread awareness and inspire individuals from all walks of life here: getinvolved.patientworthy.com Outnumber PAH | Living With Pulmonary Arterial Hypertension Together we can outnumber PAH. Find resources for living with pulmonary arterial hypertension and learn from the stories of people in the PAH community.  

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bridging-distances-in-pah-bringing-best-practices-to-the-people-through-telemonitoring/24051/ Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practitioners, further hampered by geographic isolation and constrained resources. These limitations make it difficult for healthcare providers to stay updated on new treatments, guidelines, and clinical trial data. To address these gaps, a strategic initiative is needed to enhance early detection, deliver insights on novel therapies, and promote multidisciplinary care through telementoring, aiming to improve PAH management in underserved rural areas.=

SPECIAL EDITION: Jonathan Hudson is a Global Trial Leader in Pulmonary Hypertension at Janssen Research & Development and is accompanied by colleague Josephine Garcia-Ferrer, Ph.D and Medical Manager. Jonathan and Josephine discuss Pulmonary Arterial Hypertension (PAH), the importance of clinical trials, what they entail, and share information on Janssen's UNISUS Study for adults with PAH. Learn more about UNISUS Study with the Janssen Global Trial Finder. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com 

When serial entrepreneur Martine Rothblatt (founder of Sirius XM) received her seven-year-old daughter's diagnosis of Pulmonary Arterial Hypertension (PAH), she created United Therapeutics and developed a drug to save her life. When her daughter later needed a lung transplant, Rothblatt decided to take what she saw as the logical next step: manufacturing organs for transplantation. Rothblatt's entrepreneurial career exemplifies a larger debate around the role of the firm in creating solutions for society's problems. If companies are uniquely good at innovating, what voice should society have in governing the new technologies that firms create?

This CME program highlights the latest clinical research about pulmonary arterial hypertension (PAH). PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary arteries. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. The progressive nature of this disease means that an individual may experience only mild symptoms at first, but will eventually require treatment and medical care to maintain a reasonable quality of life. There are numerous treatment options and options in development for persons with PAH and it is imperative clinicians who manage these patients stay up-to-date on the latest clinical research. This CME program, hosted by Jean Elwing, MD, of the University of Cincinnati College of Medicine. It is supported by an educational grant from Merck.To earn CME credit, go to https://checkrare.com/learning/p-pah-research-highlights-chest-2022/

Dr. Harrison Farber, a pulmonologist and director of the Pulmonary Embolism Response Team at Tufts Medical Center discusses a chronic rare disease that affects the circulatory system in the lungs and directly affects the ability of the lungs to function.Pulmonary Arterial Hypertension, or PAH, is characterized by shortness of breath, dizziness, and chest pressure. Dr. Harrison Farber joins us to discuss the impact of COVID-19 on PAH patient care.

A client has PAH—and not just regular PAH, he has advanced PAH. No, he's not spitting expletives—he has pulmonary arterial hypertension, a chronic, progressive, and ultimately terminal lung condition. He loves massage, but his therapist is concerned about the risk that blood clots might play in his disease. And—guess what—he has a history of multiple blood clots in his lungs. Is there a way to work safely here? Maybe, with the right information and careful choices about bodywork. What is PAH? And will we be seeing more of it soon? Listen in for more.   Sponsors:     Books of Discovery: www.booksofdiscovery.com     Advanced-Trainings: www.advanced-trainings.com   Host Bio:                    Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.                    Recent Articles by Ruth:          “Unpacking the Long Haul,” Massage & Bodywork magazine, January/February 2022, page 35, www.massageandbodyworkdigital.com/i/1439667-january-february-2022/36.   “Chemotherapy-Induced Peripheral Neuropathy and Massage Therapy,” Massage & Bodywork magazine, September/October 2021, page 33, http://www.massageandbodyworkdigital.com/i/1402696-september-october-2021/34.           “Pharmacology Basics for Massage Therapists,” Massage & Bodywork magazine, July/August 2021, page 32, www.massageandbodyworkdigital.com/i/1384577-july-august-2021/34.       Resources:    Pocket Pathology: https://www.abmp.com/abmp-pocket-pathology-app   Deborah Jo Levine, M.D. (2021) ‘Pulmonary Arterial Hypertension: Updates in Epidemiology and Evaluation of Patients', Supplements and Featured Publications, 27(3). Available at: https://www.ajmc.com/view/pulmonary-arterial-hypertension-updates-in-epidemiology-and-evaluation-of-patients (Accessed: 20 July 2022).   Khan, A.W. et al. (2021) ‘Pulmonary arterial hypertension post COVID-19: A sequala of SARS-CoV-2 infection?', Respiratory Medicine Case Reports, 33, p. 101429. Available at: https://doi.org/10.1016/j.rmcr.2021.101429.   Lannan, K.L., Phipps, R.P. and White, R.J. (2014) ‘Thrombosis, platelets, microparticles, and PAH: More than clot', Drug discovery today, 19(8), pp. 1230–1235. Available at: https://doi.org/10.1016/j.drudis.2014.04.001.   Pulmonary Arterial Hypertension (PAH) (no date) WebMD. Available at: https://www.webmd.com/lung/pulmonary-arterial-hypertension (Accessed: 20 July 2022).   Tudoran, C. et al. (2021) ‘Evidence of Pulmonary Hypertension after SARS-CoV-2 Infection in Subjects without Previous Significant Cardiovascular Pathology', Journal of Clinical Medicine, 10(2), p. 199. Available at: https://doi.org/10.3390/jcm10020199.   About our Sponsor:   As a Certified Advanced Rolfer™, Til was on the faculty of the Dr. Ida Rolf Institute® for 20 years, where he served as Coordinator and Faculty Chair of the Foundations of Rolfing Structural Integration program. The author of the Advanced Myofascial Techniques textbook series (which has been translated into 6 languages), his regular Myofascial Techniques and Somatic Edge columns have been featured in Massage & Bodywork magazine since 2009, and (along with Whitney Lowe) he co-hosts the popular Thinking Practitioner Podcast. He is the Director of Advanced-Trainings.com which since 1985 has offered short, credit-approved professional trainings and certification for manual therapists of all types, in person and online.   Website: Advanced-Trainings.com   Email:  info@advanced-trainings.com   Facebook:  facebook.com/Advanced.Trainings1/   Instagram: instagram.com/tilluchau   YouTube: youtube.com/user/AdvancedTrainings  

In this episode, Dr Rizzo interviews Paul M. Hassoun, MD, Johns Hopkins School of Medicine (Baltimore MD), about his research on Pulmonary Arterial Hypertension (PAH), including its pathogenesis, the evaluation required to establish the diagnosis, available therapies, and what is in store for the future direction in treating patients with the PAH.

Christopher Giordano, MS, explains how an American English major studying at Oxford University lucked into marrying a Welsh girl he convinced to move to North Carolina's Research Triangle – a hotbed of literary studies. From that beginning – somehow – Giordano got a "real job" in drug development, rising through the ranks to become president of a business unit in healthcare giant, IQVIA, and eventually, CEO of Tenax. He tells me the Tenax name comes from the word "tenacity". Of this, I have no doubt. Now listen to him spin imatinib into gold for Pulmonary Arterial Hypertension (PAH).

Chloé Temtchine, an award-winning singer/songwriter lived with Pulmonary Hypertension for 12 years. On August 5, 2020, after suffering a cardiac arrest, being in a coma for four days, and on life support (ECMO) for almost a month, Chloé received a life-saving, double-lung transplant. The surgery was performed at UCLA by the incredible Dr. Abbas Ardehali.In 2013, Chloé had just finished an album with Smash Mouth's Grammy-nominated Greg Camp. All set to go on a world tour with Camp, Chloé suffered congestive right-heart failure and was rushed to the ER. She was told she had Pulmonary Arterial Hypertension (PAH), a rare and fatal lung condition, little time left to live, and that she would have to be on oxygen for the rest of her life.To say that Chloé's world was turned upside down in an instant is not an overstatement. She had spent the previous five years dealing with a variety of physical symptoms (shortness of breath, chest pain, dry cough, body aches, racing heartbeat, fatigue, and water retention) that left many respected and acclaimed doctors at some of the most prestigious medical institutions perChloeplexed. During this time, Chloé was diagnosed with everything from pulmonary embolism to sarcoidosis to autoimmune disease. One physician even suggested that she see a psychiatrist. All of them were wrong.Chloé's story, though, is not about the years of doctor-hopping, misdiagnoses, or landing in the Critical Care Unit. It's about what happened afterwards and where she is today.Chloé left the hospital, in 2013, determined to do everything possible to boost her health and beat the odds in order to extend her lifespan. She took control of her destiny and completely altered her lifestyle, utilizing Five Key Principles: Nutritional Lifestyle, Exercise, Mindset, Creative Expression, Family & Friends.Seven years after being released from the critical care unit and many, many, many days more than doctors thought possible, Chloé was writing music, performing, and using her talent to inspire and empower those affected with PAH and other chronic illnesses. In that time, she released three albums: Be Brave, Strangers, and Lead Me Home. Chloé wrote the song Be Brave shortly after she was released from the hospital's critical care unit. Over 150,000 copies were downloaded within the first 90 days of its release. She just completed her fourth album, titled You Save Me, and is working on her fifth album. Once out of the hospital, Chloé jumped right back into songwriting mode. By 2014, Chloé (who sings with a paralyzed vocal cord and who sang with her oxygen tank that she affectionately named Steve Martin) debuted Be Brave, a song about making the choice to live despite life's challenges. See acast.com/privacy for privacy and opt-out information.

In 2013, Chloé Temtchine, a YouTube sensation and award-winning singer/songwriter, had just finished an album with Smash Mouth’s Grammy-nominated Greg Camp. All set to go on a world tour with him, Chloé suffered severe shoulder & chest pain and was rushed to the ER; she was in congestive heart failure. She was told she had Pulmonary Arterial Hypertension (PAH), a rare and fatal lung condition, little time left to live, and that she would have to be on oxygen for the rest of her life. It’s an understatement to say that Chloé’s world was turned upside down in an instant. She had spent the previous five years dealing with a variety of physical symptoms (shortness of breath, chest pain, dry cough, racing heartbeat, fatigue, and water retention) that left many respected and acclaimed doctors at some of the most prestigious medical institutions perplexed. Chloé’s doesn’t want her story to be about the years of doctor-hopping, misdiagnoses, or landing in the Critical Care Unit. She wants it to be about what happened afterward and where she is today. Seven years after being released from the critical care unit and many, many, many days more than doctors thought possible, Chloé is writing music, performing, and using her talent to inspire and empower those affected with PAH and other chronic illnesses. In that time, she released three albums: Be Brave, Strangers, and Lead Me Home. Chloé wrote the song Be Brave shortly after she was released from the hospital's critical care unit. Chloé donates proceeds from sales to the Pulmonary Hypertension Association. The video for her single “Breathe” features several children with PAH & the overarching message that sometimes you have to lose your breath to breathe. She just completed her fourth album, titled You Save Me, set to be released in tandem with Chloé’s 2020 Smile Tour.

In this episode, PHA Canada ambassador Judith Moatti discusses the importance of early diagnosis and awareness. Judith was first diagnosed with Pulmonary Arterial Hypertension (PAH) in 2009, at the young age of 25. After a long road to stability and coping with her new reality, she has become a strong advocate and spokesperson for those affected by PAH. Locally, she became a patient representative for Foundation HTAPQ (a Québec-based patient support organization) in 2012. And she also works as a support group leader for patients living or affected by PH in her region. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #LifeInPurple #PHUnited #ClinicalTrials @antidote_me @PHACanada  www.sometimesitsph.ca

Betty Lou “Wojo” is a retired school teacher who lost her husband Jerry and two children (Michael and Matthew) to Pulmonary Arterial Hypertension (PAH), a rare blood vessel disorder that affects people of all ages and causes high blood pressure in the arteries of the lungs that can lead to heart failure. Betty Lou discusses how she turned her sorrow into strength and why the Wojo family has established PH research grants in Jerry, Michael and Matthew’s names. Learn more about pulmonary hypertension at phaware365.global. Never miss an episode with the phaware® podcast app. Follow us @phaware on facebook, twitter, instragram, youtube & linkedin #phaware

Host: Jennifer Caudle, DO Guest: K. Akaya Smith, MD Pulmonary Arterial Hypertension (PAH): Who is at greatest risk for developing it? What do practitioners need to know about diagnosing, treatment and the overall prognosis? Host Dr. Jennifer Caudle welcomes Dr. Akaya Smith, Medical Director for Pulmonary Hypertension Program and Assistant Professor of Medicine at the Hospital of the University Pennsylvania. Dr. Smith answers these questions, as well as, the Penn Center of Excellence for Pulmonary Hypertension.

Host: Jennifer Caudle, DO Guest: K. Akaya Smith, MD Pulmonary Arterial Hypertension (PAH): Who is at greatest risk for developing it? What do practitioners need to know about diagnosing, treatment and the overall prognosis? Host Dr. Jennifer Caudle welcomes Dr. Akaya Smith, Medical Director for Pulmonary Hypertension Program and Assistant Professor of Medicine at the Hospital of the University Pennsylvania. Dr. Smith answers these questions, as well as, the Penn Center of Excellence for Pulmonary Hypertension.

Terence K. Trow, MD, FCCP (one of the authors for the new Pharmacologic Therapy for Pulmonary Arterial Hypertension (PAH) in Adults CHEST Guideline and Expert Panel Report); Mary G. George, MD (corresponding author of the new CDC pulmonary hypertension surveillance report); and editorialist Anna R. Hemnes, MD, join CHEST Podcast Editor D. Kyle Hogarth, MD, FCCP to review these important articles. The new CHEST PAH Guidelines distill the available evidence on new therapies and treatment. Among the points emphasized by Dr. Trow is the need to use more than echocardiograms in diagnosis; right-sided heart catheterization is also required. Dr. George reviews the data from the National Vital Statistics System and from the National Hospital Discharge Survey, noting that after a period of decline, the mortality associated with PH among men is beginning to rise; a rise among women also continues.